Amgen (AMGN) presents strong performances in recent times. As mentioned, the results of the Q3 earnings show that both revenues and profits exceeded the expected results. The multinational biopharmaceutical corporation's portfolio continues to strengthen with its new drug being significantly important, along with gaining a full
FDA approval for additional drugs. There is further promising news with its weight-loss data set to come at the end of the year. Results of trials, such as the
Repatha Phase 3 trial, are proving to be effective showing promising impacts on cardiovascular health plus, the success of beating Q3 expectations boosted AMGN by 7.3%. The narrative has not been one-sided, however. Notable insider selling and decreasing positions from several investment firms are witnessed. Amgen’s
IMDELLTRA extending ES-SCLC survival by five months has been a significant headline as well. Lastly, a more bullish future is predicted as Amgen raises its full-year outlook after a significant jump in third-quarter profit and sales.
Amgen AMGN News Analytics from Sun, 27 Jul 2025 07:00:00 GMT to Sat, 22 Nov 2025 13:03:13 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor 3
